The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
暂无分享,去创建一个
H. Parving | P. Arner | H. Lehnert | R. Gomis | S. Andersen | H Lehnert | R Gomis | J. Bröchner-Mortensen | P Arner | H H Parving | J Bröchner-Mortensen | S Andersen | Hendrik Lehnert | Jens Bröchner-Mortensen
[1] L. Groop,et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. , 1994, JAMA.
[2] A. H. Norris,et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. , 1976, Journal of gerontology.
[3] Philip D. Harvey,et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.
[4] J. García-Puig,et al. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. , 1996, Journal of human hypertension.
[5] G. Remuzzi,et al. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? , 1990, Kidney international.
[6] S. Leurgans,et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. , 1996, Kidney international.
[7] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[8] H. Parving,et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria , 1999, BMJ.
[9] K. Resch,et al. Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. , 1994, Kidney international.
[10] A. Tiengo,et al. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients , 1995 .
[11] H. Parving,et al. Prevention of diabetic renal disease with special reference to microalbuminuria , 1995, The Lancet.
[12] L. Groop,et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria , 1994 .
[13] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[14] H. Parving,et al. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. , 2000, Kidney international.
[15] O. Pedersen,et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.
[16] H. Seelig. Die Jaffé-Reaktion mit Kreatinin Reaktionsprodukt und allgemeine Reaktionsbedingungen , 1969 .
[17] M. Pahor,et al. Outcome Results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in Patients With Hypertension and NIDDM , 1998, Diabetes Care.
[18] N. Chaturvedi. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.
[19] Y. Lacourciére,et al. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. , 1993, Hypertension.
[20] G. Navis,et al. Renoprotective therapy: titration against urinary protein excretion , 1999, The Lancet.
[21] H. Lebovitz,et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. , 1994, Kidney international. Supplement.
[22] G. Beck,et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. , 1996, The New England journal of medicine.
[23] M. Lishner,et al. Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients , 1993, Annals of Internal Medicine.
[24] D. Cox. Regression Models and Life-Tables , 1972 .
[25] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[26] H. Parving. Initiation and progression of diabetic nephropathy. , 1996, The New England journal of medicine.
[27] J. Chan,et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. , 2000, Kidney international.
[28] R. Schrier,et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. , 2000, Diabetes care.
[29] D. Goldstein,et al. Glycated hemoglobin: methodologies and clinical applications. , 1986, Clinical chemistry.
[30] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .